CliffBio
small molecule

TIVICAY

DOLUTEGRAVIR SODIUM

Loss of exclusivityJune 2030latest FDA-listed patent expiry
CompanyViiV Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameTIVICAY
Active ingredientDOLUTEGRAVIR SODIUM
StrengthEQ 50MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2013
Marketing statusRX

Listed patents

PatentExpiresType
9242986*PEDJune 2030—
9242986December 2029substance, product
8129385*PEDApril 2028—
8129385October 2027substance, product

More from ViiV Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.